Prognostic and predictive validation of molecular markers in rare diseases

Dr. rer. nat. Rene Schmidt

Weitere beteiligte Personen:
Univ.-Prof. Dr. Andreas Faldum

BMBF Gesundheitsforschung (2010-2012), Eigenmittel

Laufzeit: seit 2009


Pietsch T*, Schmidt R*, Remke M, Korshunov A, Hovestadt V, Jones D TW, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren A., Friedrich C, Skladny H, Fleischhack G, Taylor MD, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S* and Pfister SM* (2014): Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol, Volume 128, Issue 1, 137-149. *These authors contributed equally.

Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Hero B, Berthold F (2019). A new risk score for patients with first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis. Cancer Medicine 8(17): 7236-7243.

Rosswog C*, Schmidt R*, Oberthuer A, Juraeva D, Brors B, Engesser A, Kahlert Y, Volland R, Bartenhagen C, Simon T, Berthold F, Hero B, Faldum A, Fischer M (2017). Molecular classification substitutes the prognostic variables stage, age, and MYCN status in neuroblastoma risk assessment. Neoplasia 19(12): 982-990. * These authors contributed equally